{
  "id": "breast-cancer-cdk46-by-payer",
  "display_name": "ER+/HER2- MBC (By Payer)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, All Patients, by Payer, Q1 2023",
  "insight_type": "Treatment Patterns by Payer",
  "summary": "CDK4/6 inhibitor utilization varies by payer, with Medicare patients receiving guideline-concordant care at 83% while Commercial patients are at only 72%.",
  "recommendation": "Address payer-specific barriers to CDK4/6 inhibitor utilization, particularly for commercial insurance patients.",
  "financial_impact": 190000,
  "financial_impact_description": "Improving CDK4/6 inhibitor utilization in patients with commercial insurance could generate approximately $190,000 in annual savings.",
  "peer_financial_impact": 230000,
  "peer_financial_impact_description": "Peer organizations achieve better utilization with commercial payers, representing a $230,000 opportunity.",
  "action_steps": [
    "Analyze approval rates and rejection reasons for commercial payers",
    "Develop payer-specific prior authorization support",
    "Implement financial counseling protocols for high cost-sharing plans"
  ],
  "peer_action_steps": [
    "Benchmark against organizations with higher commercial payer utilization",
    "Develop specific strategies for working with challenging payers",
    "Consider contracting strategies that facilitate appropriate CDK4/6 use"
  ],
  "chart_data": {
    "categories": ["Medicare", "Commercial", "Medicaid", "Uninsured", "Other"],
    "values": [83, 72, 78, 65, 70],
    "peer_values": [85, 80, 78, 65, 75],
    "target_values": [85, 85, 85, 75, 80]
  },
  "drilldowns": []
} 